Sign in

    Chun Chen

    Research Analyst at UBS

    Chun Chen is an Executive Director and Equity Research Analyst at UBS, specializing in the coverage of China A-share and Hong Kong-listed TMT (Technology, Media, and Telecommunications) companies. She covers prominent names such as Baidu, JD.com, Meituan, and Alibaba, and is recognized for her differentiated insights on the Chinese internet sector, with her research frequently cited by institutional investors. Chun Chen began her career as an analyst at CITIC Securities before joining UBS in 2015, steadily progressing to her current leadership role. She holds professional credentials including the CFA designation and is registered with relevant securities regulatory authorities, highlighted by her consistent recognition in industry polls for research quality.

    Chun Chen's questions to BRISTOL MYERS SQUIBB (BMY) leadership

    Chun Chen's questions to BRISTOL MYERS SQUIBB (BMY) leadership • Q3 2024

    Question

    Chun Chen inquired about the recent PRMT5 inhibitor data, asking about the durability of response and which tumor types the company plans to prioritize for further development.

    Answer

    Head of Global Drug Development Samit Hirawat described the data as very encouraging, highlighting non-small cell lung cancer (NSCLC) with a ~31% overall response rate and a 10.5-month duration of response. He also noted promising activity in pancreatic cancer and stated that an update on later-phase development plans would be provided next year.

    Ask Fintool Equity Research AI